Unassociated Document



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
____________

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act Of 1934

October 3, 2005
Date of Report (Date of earliest event reported) 
___________________________________________________________

ACURA PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
___________________________________________________________
 

 
State of New York 
   1-10113
  11-0853640
(State of Other Jurisdiction
(Commission File Number)
 (I.R.S. Employer
of Incorporation)
  
Identification Number)
     
616 N. North Court, Suite 120
Palatine, Illinois 60067
(Address of principal executive offices) (Zip Code)

(847) 705-7709
(Registrant's telephone number, including area code)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)

o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-2(b))

o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e- 4(c)) 
Item 8.01 Other Events

On October 3, 2005, Acura Pharmaceuticals, Inc. (the "Company") issued a press release announcing the Company's receipt of communication from the U.S. Food and Drug Administration ("FDA") requesting certain non-clinical studies relating to the Company's Product Candidate #2. A copy of the Company's Press Release is attached hereto as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

Exhibit
Number
Description

99.1
Press Release dated October 3, 2005 Announcing Receipt of FDA Communication.





SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
     
  ACURA PHARMACEUTICALS, INC.
 
 		  
 		  
 
Date: October 3, 2005 By:   /s/ Peter A. Clemens
 
Peter A. Clemens
  Vice President & Chief Financial Officer




EXHIBIT INDEX

Exhibit
Number
Description

99.1
Press Release dated October 3, 2005 Announcing Receipt of FDA Communication.